TY - JOUR
AU1 - Mehta, Nidhi
AU2 - deGoma, Emil
AB - Despite the best available medical therapy inclusive of statins, substantial residual risk remains for atherothrombotic cardiovascular disease. Non-statin lipid-lowering therapy may help address this critical unmet need through reduction of the levels of low-density lipoprotein and other atherogenic lipoproteins. In the past few years, several landmark trials have provided important information regarding the efficacy and safety of non-statin therapy for dyslipidemia and cardiovascular risk reduction.
TI - Pharmacologic Interactions of Multidrug Therapy for Dyslipidemia
JF - Current Atherosclerosis Reports
DO - 10.1007/s11883-012-0303-7
DA - 2013-01-09
UR - https://www.deepdyve.com/lp/springer-journals/pharmacologic-interactions-of-multidrug-therapy-for-dyslipidemia-9IbheoE3bf
SP - 1
EP - 8
VL - 15
IS - 2
DP - DeepDyve
ER -